L eukotrienes ("leuko," from white blood cells; and "trienes," three conjugated double bonds) comprise a family of products of the 5-lipoxygenase pathway of arachidonic acid metabolism. The cysteinyl leukotrienes C 4 , D 4 , and E 4 account for the biologic activity that was previously termed "slow-reacting substance of anaphylaxis," and the efficacy of antagonists to type 1 cysteinyl leukotriene receptor (CysLT 1 ) in asthma validates the importance of cysteinyl leukotrienes and CysLT 1 in this disease. 1 This article reviews both established understanding and recent advances in our knowledge about leukotrienes.
S y n the sis of L euko t r iene s
The synthesis of leukotrienes from substrate arachidonic acid is initiated by 5-lipoxygenase in concert with 5-lipoxygenase-activating protein (FLAP) 2 (Fig. 1) . Although FLAP does not have enzymatic activity, it enhances the ability of 5-lipoxygenase to interact with its substrate. Leukotriene A 4 (LTA 4 ) is converted by LTA 4 hydrolase to leukotriene B 4 (LTB 4 ), or it can be conjugated with reduced glutathione by leukotriene C 4 (LTC 4 ) synthase to yield LTC 4 . LTB 4 and LTC 4 are exported from the cell by specific transporter proteins; the released LTC 4 is converted to leukotriene D 4 (LTD 4 ), which undergoes conversion to leukotriene E 4 (LTE 4 ) by sequential amino acid hydrolysis. The capacity to generate large amounts of leukotrienes from arachidonate is largely confined to leukocytes; however, the amounts of LTB 4 and cysteinyl leukotrienes that various types of leukocytes produce depend on the distal enzymes LTA 4 hydrolase and LTC 4 synthase, respectively (Table 1 and Glossary) .
Although nonleukocyte cells generally do not have sufficient 5-lipoxygenase and FLAP to synthesize appreciable amounts of leukotrienes from arachidonate, such cells expressing distal LTA 4 -metabolizing enzymes can take up leukocyte-derived LTA 4 and metabolize it into bioactive leukotrienes, a process that is termed "transcellular biosynthesis." 3 The interaction between neutrophils and endothelial cells is an example of this phenomenon: a neutrophil (the donor cell) containing 5-lipoxygenase provides LTA 4 to the endothelial cell (the acceptor cell), which lacks 5-lipoxygenase but expresses LTC 4 synthase and can thereby metabolize the donated LTA 4 to LTC 4 . Products of the 5-lipoxygenase pathway besides leukotrienes (5-hydroxyeicosatetraenoic acid, 5-oxo-eicosatetraenoic acid, 4 and lipoxins 5 ) are not considered in this review.
The output of the leukotriene synthetic pathway is regulated by the amount of free arachidonate that phospholipase A 2 releases from cell-membrane phospholipids, 6,7 the level of each of the proteins in the 5-lipoxygenase pathway, the catalytic activity per enzyme molecule (e.g., modulated by protein kinase-directed phosphorylation 8 ), and the availability of small molecules (e.g., ATP, nitric oxide, 9 and reactive oxygen intermediates) that modulate 5-lipoxygenase activity.
Another variable that influences leukotriene synthesis is the intracellular localization of 5-lipoxygenase. In resting leukocytes, this enzyme can reside in the cytoplasm or the nucleoplasm, and it shuttles between them by regulated nuclear import and export processes. When 5-lipoxygenase is activated, it relocates to the outer or inner nuclear membrane. 10 The movement of 5-lipoxygenase from the nucleoplasm to the inner nuclear membrane is associated with a maximal synthesis of LTB 4 . 11 Heritable deficiencies of enzymes in the leukotriene synthetic pathway are rare, 12 but there are allelic variants of the coding and promoter regions of the genes for 5-lipoxygenase, 13 
L euko t r iene R ecep t or s
Leukotrienes act by binding to specific heptahelical receptors of the rhodopsin class that are located on the outer plasma membrane of structural and inflammatory cells. 20, 21 Once ligated by the leukotriene, these receptors interact with G proteins in the cytoplasm, thereby eliciting increases in intracellular calcium and reductions in intracellular cyclic AMP. These proximal signals activate downstream kinase cascades in ways that alter various cellular activities, ranging from motility to transcriptional activation. Table 1 lists the major types of cells that express leukotriene receptors.
Type 1 cysteinyl leukotriene receptor (CysLT 1 ) 22 mediates sustained bronchoconstriction, mucus secretion, and edema in the airways. Selective antagonists of CysLT 1 that are approved for the treatment of asthma block the proasthmatic effects of CysLT 1 (Fig. 1) . Experiments in mice that are deficient in type 2 cysteinyl leukotriene receptor (CysLT 2 ) 23 or that overexpress CysLT 2 in the lungs 24 indicate that CysLT 2 does not mediate bronchoconstriction but, rather, contributes to inflammation, vascular permeability, and tissue fibrosis. There are no known specific antagonists of CysLT 2 . Certain reported actions of cysteinyl leukotrienes are not readily explained by either CysLT 1 or CysLT 2 , raising the possibility of the presence of CysLT 1 -CysLT 2 heterodimers or additional receptors. 25 One candidate is G protein-coupled receptor 17 (GPR17), a dual-uracil nucleotide-cysteinyl leukotriene receptor. 26 B leukotriene receptor 1 (BLT 1 ) is the high-affinity receptor for LTB 4 that mediates most, if not all, of its chemoattractant and proinflammatory action. 20 B leukotriene receptor 2 (BLT 2 ) is a lower-affinity receptor for LTB 4 that also binds other lipoxygenase products; little is known about its physiological function.
The expression of CysLT 1 can be influenced at the transcriptional level by type 2 helper T (Th2)-cell-type cytokines. 27 This effect probably explains why CysLT 1 is overexpressed in patients with asthma or chronic rhinosinusitis who have aspirin sensitivity and why levels of the receptor return to normal after aspirin desensitization. 28 In addition to the actions of cysteinyl leukotrienes in the airway, they join LTB 4 in exerting other biologic actions. Some of the actions of cysteinyl leukotrienes and LTB 4 are distinctive (e.g., smooth-muscle contraction for the former and (Fig. 1) include montelukast, zafirlukast, and pranlukast (the last available only in Japan). The only other antileukotriene drug that has been approved by the Food and Drug Administration (FDA) is zileuton, which directly inhibits 5-lipoxygenase; this effect blocks production of cysteinyl leukotrienes and LTB 4 . Zileuton inhibits an estimated 26 to 86% of endogenous leukotriene production. 41 The clinical use of zileuton is limited by the need to monitor hepatic enzyme levels and to administer the drug four times daily. A twice-daily sustained-release form of zileuton has recently received FDA approval. Other candidate 5-lipoxygenase inhibitors also have hepatotoxicity. The hepatic injury caused by zileuton appears to be a direct toxic effect that is unrelated to inhibition of 5-lipoxygenase. 42 An alternative way of blocking leukotriene synthesis is to inhibit FLAP. The crystal structure of this molecule has recently been reported, 43 and this information should prove useful in drug design. One FLAP inhibitor, DG031 (veliflapon, DeCode Genetics), is being reformulated for use in phase 3 trials for the prevention of myocardial infarction. Selective BLT 1 antagonists that have been developed up to now have been tested in animal models of disease, 44 but none have emerged for clinical use.
L euko t r iene s in Dise a se
Leukotrienes have a multitude of biologic actions (Table 2 ) and have been suggested as factors in numerous disease processes (Table 3 ). The role of leukotrienes has been validated in clinical trials of antileukotriene agents for asthma and only a few of the other diseases listed in Table 3 .
Asthma

Antileukotriene Drugs as Controller Agents
The benefits of antileukotriene therapy (i.e., 5-lipoxygenase inhibition by zileuton 45 and CysLT 1 blockade by montelukast or zafirlukast 46,47 ) in children and adults with asthma are improved pulmonary function, decreased daytime and nocturnal symptoms, a reduced need for short-acting rescue β 2 agonists, fewer exacerbations of asthma, and an increased quality of life. Inhaled corticosteroids are more potent than antileukotriene agents 48 and hence are favored as first-line treatment; however, antileukotriene therapy can be used initially in a patient who cannot or will not take corticosteroids. 49 Antileukotriene agents have an additive benefit in patients whose disease is not adequately controlled by inhaled corticosteroids, 50 perhaps reflecting the inability of corticosteroids Increased production and motility of CD34+ progenitors
Increased adhesion
Increased transmigration By ligating their specific cognate receptors (which are summarized in Table 1 ), leukotrienes promote the accumulation and function of virtually all subgroups of leukocytes at sites of inflammation. Such responses are important in the pathogenesis of diseases, including asthma, cardiovascular disease, and cancer. Leukotrienes affect leukocytes by stimulating the growth of bone marrow CD34+ pluripotent hematopoietic stem-cell progenitors and their subsequent migration into the bloodstream. Leukotrienes also increase the expression of adhesion proteins (thereby enhancing leukocyte adhesion to the microvasculature) and promote cell motility, which leads to transmigration into tissues. Once leukocytes reach the inflamed tissues, their survival and activation are enhanced by leukotrienes. Through B leukotriene receptor 1 (BLT 1 ), leukotriene B 4 (LTB 4 ) primarily mediates the recruitment of mast cells, neutrophils, monocytes or macrophages, and T cells; through type 1 cysteinyl leukotriene receptor (CysLT 1 ), cysteinyl leukotrienes, including leukotriene D 4 (LTD 4 ), promote the recruitment of eosinophils, dendritic cells, and T cells. to inhibit leukotriene pathways. Although the weight of evidence from randomized, controlled studies indicates that antileukotriene agents are inferior to long-acting β 2 agonists as add-on therapy to inhaled corticosteroids (particularly with respect to improving lung function 51 ), some studies have shown that montelukast is similar to longacting β 2 agonists in reducing symptoms and exacerbations of asthma. 52, 53 Some patients with asthma are particularly good candidates for antileukotriene therapy. One example is the patient with allergic rhinitis. The nasal congestion and rhinorrhea in allergic rhinitis are reduced by montelukast to a degree similar to that with antihistamines but inferior to that with topical corticosteroids. [54] [55] [56] Since allergic rhinitis is often present with asthma and complicates its management, a leukotriene modifier could improve upper-and lower-airway symptoms and signs. 57 However, trials of the use of montelukast to reduce the need for other rhinitis medications in patients with both asthma and allergic rhinitis have had divergent results. 58, 59 Montelukast also provides protection against exercise-induced asthma. A single oral dose of montelukast is as effective as inhaled salmeterol, a long-acting β 2 agonist, in preventing exerciseinduced asthma, 60 and its regular use during a 2-month period was not associated with the development of tachyphylaxis, as occurs with the use of salmeterol. 61 Antileukotriene agents are beneficial in patients with aspirin-sensitive asthma, a condition in which production of very high levels of cysteinyl leukotrienes is typical. 62,63 However, even among such patients, the drugs are inconsistent in their abil- 
Effects of Antileukotriene Agents on Airway Remodeling
Structural alterations referred to as "airway remodeling," consisting of increases in the number of airway goblet cells and smooth-muscle mass, as well as deposition of subepithelial collagen ( 
Responsiveness to Antileukotriene Agents
Since asthma involves multiple mediators, it is not surprising that the efficacy of agents that target only components of the 5-lipoxygenase pathway is limited and variable. Why are antileukotriene drugs effective in some patients and ineffective in others? One explanation for the efficacy of these drugs is that CysLT 1 signaling contributes to many aspects of asthma pathogenesis besides constriction of bronchial smooth muscle. For example, CysLT 1 influences systemic immune responses and has bidirectional interactions with cytokines. The interplay between the Th2 cytokine interleukin-13 and cysteinyl leukotrienes and CysLT 1 exemplifies such relationships (Fig. 3) .
Variations in responses of patients with asthma to corticosteroids and β 2 agonists were illuminated by studies of an antileukotriene agent. 72 In randomized, controlled trials with these drugs, symptoms were reduced as compared with baseline in 60 to 80% of patients, whereas improvements in lung function were noted in only 35 to 50% of such patients. 73 This discordance in outcome measures may be due to differences among patients in leukotriene biology, genotype, or clinical characteristics. After spontaneous episodes of bronchospasm in patients with asthma or after challenge with allergen, exercise, or aspirin in susceptible patients, levels of cysteinyl leukotrienes increase in airway fluids and urine. 74, 75 Urinary LTE 4 , a measure of whole-body synthesis of cysteinyl leukotrienes, 76 is a possible predictor of drug responsiveness, and significant associations between high urinary LTE 4 levels and responsiveness to antileukotriene agents have been reported. 77 Other studies, however, have shown either no such relationship 63 or an inverse relationship. 78 It seems that technical limitations and spontaneous variations in the level of urinary LTE 4 reduce its value as a robust predictor of the response to antileukotriene therapy in individual patients. Leukotriene synthesis by cultured leukocytes is also an unreliable predictor of the clinical response to pranlukast. 79 In patients with asthma who were treated with a 5-lipoxygenase inhibitor, polymorphisms in the promoter of the 5-lipoxygenase gene (ALOX5) were associated with diminished improvement in airflow. 80 However, since these genetic variants occur in less than 10% of patients with asthma, they can explain only a fraction of the unresponsiveness to leukotriene modifiers. By contrast, an A-to-C transversion in the LTC 4 synthase promoter region occurs in approximately 20 to 40% of patients with asthma 16 and is associated with increased synthesis of cysteinyl leukotrienes. A positive relation between this variant allele and the clinical response to various CysLT 1 antagonists was reported in two studies 81,82 but not in a third. 83 A variant allele in the coding region of the gene encoding CysLT 2 has recently been reported to be associated with an enhanced response to montelukast. 84 It is likely that these pharmacogenetic associations vary according to the geographic origin of the population under analysis. Since levels of leukotrienes and their receptors are greatly influenced by substances such as cytokines, analysis of responsiveness to antileukotriene therapy must take into account the genes for Interleukin-13, a product derived from type 2 helper T (Th2) lymphocytes that participates in the development of asthma, can up-regulate both the leukocyte biosynthesis of leukotriene D 4 (LTD 4 ) and the expression of cellular type 1 cysteinyl leukotriene receptors (CysLT 1 ). Moreover, LTD 4 can up-regulate production of interleukin-13, as well as the expression of its receptor. The result of this cross-talk is a self-perpetuating circuit of inflammation and smooth-muscle contraction in which interleukin-13 and its receptor mediate some of the actions of LTD 4 and LTD 4 -CysLT 1 mediates some of the actions of interleukin-13. molecules that reside outside the leukotriene pathway. Several characteristics of patients have been associated with responsiveness to antileukotriene drugs. A benefit is more likely in children than in adults 85 and in younger children than in older children. 86 Moreover, acquired factors such as obesity and smoking may be relevant in understanding the clinical effects of antileukotriene agents. Although in one study the effect of inhaled beclomethasone on asthma control declined with increasing body-mass index, no such decline was observed for montelukast, 87 suggesting that the relative benefit of montelukast may have been greater in more obese patients. Likewise, patients with asthma who smoked had a greater response to montelukast than did their nonsmoking counterparts. 88 
Therapeutic Trials of Antileukotriene Agents
Since it is impossible to predict responsiveness to antileukotriene therapy in an individual patient, a therapeutic trial in the patient may be necessary. Improvements in symptoms or a reduced need for rescue bronchodilators can be seen with antileukotriene therapy as early as the first day of treatment, since cysteinyl leukotrienes increase bronchial tone. 46,89 Reductions in levels of exhaled nitric oxide 90 and bronchial hyperresponsiveness 91 occur within 1 week and 2 weeks after the initiation of therapy, respectively, and improvements in lung function and symptoms occur over a period of weeks or months. 52,73 A trial period of 1 to 2 months is recommended.
Montelukast is the most commonly used inhibitor of the leukotriene pathway because of its ease of use, good safety profile, and once-daily regimen. However, use of this CysLT 1 antagonist ignores possible contributions of CysLT 2 to effects mediated by cysteinyl leukotrienes. Montelukast also does not inhibit other products of the 5-lipoxygenase pathway - most notably, LTB 4 . The lack of an effect on LTB 4 could be important, because this leukocyte chemoattractant and activator is probably involved in severe asthma and asthma exacerbations. A 5-lipoxygenase inhibitor might therefore have better efficacy than a CysLT 1 antagonist. Although retrospective data support the possibility that zileuton is more effective in severe asthma than in mild asthma, 92 there are no data from large-scale, prospective comparisons of an inhibitor of leukotriene synthesis with a CysLT 1 antagonist.
Cardiovascular Disease
The role of leukotrienes in cardiovascular disease has been the subject of intense investigation (Tables 2 and 3). Atherosclerotic vascular lesions express the entire cassette of leukotriene biosynthetic proteins (5-lipoxygenase, FLAP, LTA 4 hydrolase, and LTC 4 synthase) and receptors (CysLT 1 , CysLT 2 , BLT 1 , and BLT 2 ). Moreover, levels of 5-lipoxygenase correlate with the severity of the atherosclerotic lesion 93 and plaque instability. 94 Studies in animals and in vitro suggest that both LTB 4 and cysteinyl leukotrienes participate in the development of atherosclerotic lesions. LTB 4 , by promoting BLT 1 -mediated intracellular signaling, contributes to recruitment of monocytes and foam-cell differentiation, 95 as well as intimal hyperplasia. 96 Cysteinyl leukotrienes - probably involving signaling mediated by both CysLT 1 and CysLT 2 -enhance the recruitment of leukocytes into the arterial wall and contribute to thrombosis and vascular remodeling 97, 98 (Fig. 2 and Table 2 ).
The incidence of strokes and myocardial infarctions in European, Japanese, and American black populations has been linked to variants of the genes that encode FLAP and LTA 4 hydrolase; these variants result in overproduction of leukotrienes. 14,15,99 In a 4-week pilot study, Icelandic patients with a history of myocardial infarction and one of the variant genes that encodes FLAP or LTA 4 hydrolase who were treated with the investigational FLAP inhibitor DG031 (veliflapon) had a significant reduction in levels of C-reactive protein, a biomarker of inflammation that has been linked to cardiovascular disease. 100 In a population of predominantly white North Americans, the association of variants of the FLAP gene with cardiovascular disease is less clear. Two studies in the United States showed no association between variants of FLAP and the risk of ischemic stroke, 101,102 and one of the studies also showed no association between these alleles and myocardial infarction. 102 Another U.S.-based study showed an association between FLAP variants and ischemic strokes among whites but not blacks. 103 Other polymorphisms involving the 5-lipoxygenase pathway have been linked to atherosclero- sis. In women, an A-to-C transversion in the LTC 4 synthase promoter region has been associated with an age-adjusted risk of increased levels of coronary-artery calcium and an increased mean intimal-medial thickness of the carotid artery, 104 a surrogate measure of atherosclerosis. Carotid intimal-medial thickness was also shown to be increased in carriers of two variant alleles of the 5-lipoxygenase promoter in a North American population. 105 The same 5-lipoxygenase promoter polymorphisms were not associated with an increased risk of myocardial infarction in a Spanish population. 106 Taken together, these data suggest a role of leukotrienes in the development of atherosclerotic vascular disease, and genetic studies suggest a population-specific influence of polymorphisms in genes encoding leukotriene biosynthetic enzymes or leukotriene receptors.
Cancer
Chronic inflammation can increase the risk of cancer. Cysteinyl leukotrienes and LTB 4 that are released by inflammatory cells infiltrating the mucosa of the gut in inflammatory bowel disease may be mediators of such malignant transformation (Table 2) . LTD 4 activates β-catenin signaling, leading to the up-regulation of the antiapoptotic protein Bcl-2 and increased cell survival. 107 As compared with normal intestinal epithelial cells, colorectal adenocarcinomas have increased nuclear localization of CysLT 1 , which may facilitate proliferation of the malignant cells by kinase signaling. 108 LTB 4 signaling has also been associated with cancer-cell proliferation. In colon-cancer tissue and cell lines, there is increased expression of BLT 1 , and when BLT 1 is suppressed in cultured cells by a small interfering RNA, cell proliferation decreases. 109 Malignant cells in colorectal, esophageal, and pancreatic adenocarcinomas, bronchogenic carcinoma, melanoma, lymphomas, and leukemias express large amounts of 5-lipoxygenase, FLAP, and other leukotriene biosynthetic enzymes. 110, 111 In one study, treatment of 5-lipoxygenase-expressing esophageal cancer cell lines with a 5-lipoxygenase inhibitor decreased cell survival. 112 The effects of the inhibitor paralleled reductions in LTB 4 production and could be reversed by exogenous LTB 4 , which indicated that the decreased cell survival was due to interruption of LTB 4 synthesis. Chronic lymphocytic leukemia cells express large amounts of 5-lipoxygenase and BLT 1 , and treatment with an investigational inhibitor of 5-lipoxygenase or FLAP blocks the CD40-dependent activation of these cells; this effect is reversed by the addition of LTB 4 to the cultured cells. 113 In a mouse model of lung cancer, a FLAP inhibitor that reduces leukotriene synthesis reduced the volume of lung tumors induced by a tobacco-specific carcinogen. 114 In rats with a gastroesophageal reflux disease similar to Barrett's esophagus, an esophageal adenocarcinoma that overexpresses LTA 4 hydrolase developed; inhibition of LTB 4 synthesis by the LTA 4 hydrolase inhibitor bestatin reduced the incidence and volume of such tumors. 115 Administration of both zileuton and bestatin also reduced the incidence of carcinogen-induced oral squamous-cell carcinoma in hamsters. 116 These results are the basis of an ongoing clinical trial sponsored by the National Cancer Institute to test the idea that interruption of leukotriene synthetic pathways or leukotriene receptors reduces the growth of cancer. 114 L euko t r iene s in A n t imicrobi a l Defense
Leukotrienes that are synthesized in response to a spectrum of infectious agents enhance the capacities of macrophages and neutrophils to ingest and kill microbes and to produce antimicrobial mediators. 117 LTB 4 -BLT 1 signaling exerts broader and more potent effects in this regard than does signaling between cysteinyl leukotrienes and CysLT 1 . In animal models of infection, genetic or pharmacologic interruption of leukotriene synthesis or signaling impairs local microbial clearance. 117 For example, lungs of 5-lipoxygenase-null mice contain almost 100 times as much Klebsiella pneumoniae as do lungs of wild-type animals 48 hours after intrapulmonary bacterial inoculation. In humans, acquired states of leukotriene deficiency have been described in human immunodeficiency virus (HIV) infection 118 and proteincalorie malnutrition. 119 In HIV infection, leukotriene deficiency is the result of reduced expression of 5-lipoxygenase and, especially, of FLAP. These reductions are a consequence of a deficiency of CD4 T-cell-derived cytokines that stimulate the production of these elements in the leukotriene pathway. 118 Although patients with asthma who are treated with antileukotriene agents do not have an increased risk of infection, a significant in-crease in the risk of infectious pulmonary exacerbations was reported in patients with cystic fibrosis who were treated with an investigational BLT 1 antagonist (BIIL 284), necessitating early termination of the clinical trial. 120
C onclusions
Today, nearly three decades since leukotrienes were discovered and one decade since drugs targeting this pathway became available, new and often unexpected insights into the biology and clinical importance of these lipid mediators continue to emerge. Beyond the classically recognized and validated participation of cysteinyl leukotrienes in asthma, it is now evident that leukotrienes are multifunctional mediators that influence many biologic responses and probably play a role in other diseases.
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